General Information
Drug ID
DR00403
Drug Name
Paroxetine
Synonyms
(-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine; (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)methyl)piperidine; (-)-Paroxetine; (-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine; (-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine; (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine; (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; (3S-trans)-3-[(1,3-Benzodioxol-5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine; 3-(Benzo[1,3]Dioxol-5-Yl-Oxymethyl)-4-(4-Fluoro-Phenyl)-Piperidine Hydrochloride; Aropax; BRL 29060; BRL-29060; Casbol; FG 7051; FG-7051; Frosinor; Motivan; NNC-20-7051; Paroxetina; Paroxetina [INN-Spanish]; Paroxetine (TN); Paroxetine (USP/INN); Paroxetine Hcl; Paroxetine [USAN:INN:BAN]; Paroxetinum; Paroxetinum [INN-Latin]; PaxPar; Paxetil; Paxil; Paxil (TN); Paxil CR;Seroxat CR; Pexeva; Seroxat; Seroxat (TN); [3H]Paroxetine
Drug Type
Small molecular drug
Indication Depression [ICD11: 6A8Z] Approved [1]
Therapeutic Class
Antidepressants
Structure
3D MOL 2D MOL
Formula
C19H20FNO3
Canonical SMILES
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4
InChI
InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1/i5T
InChIKey
AHOUBRCZNHFOSL-RXMHWKDRSA-N
CAS Number
CAS 61869-08-7
Pharmaceutical Properties Molecular Weight 331.4 Topological Polar Surface Area 39.7
Heavy Atom Count 24 Rotatable Bond Count 4
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 5
XLogP
3.5
PubChem CID
53316721
PubChem SID
124956274 , 160857041 , 178101282 , 223868935
ChEBI ID
ChEBI:7936
TTD Drug ID
D06GDY
DT(s) Transporting This Drug P-GP Transporter Info P-glycoprotein 1 Substrate [2]
References
1 Paroxetine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.